News | BTG Specialty Pharmaceuticals

Date

Title

21 Sep 2023

BTG Pharmaceuticals, a SERB company, to present data on ricin antidote development programme at the North American Congress of Clinical Toxicology
13 Jul 2023

SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat Therapeutics
22 Jun 2023

BTG Pharmaceuticals Statement on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Use of Glucarpidase (Voraxaze®) and MTXPK.org
11 May 2023

SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent
02 May 2023

New Publication Compares Total Vials of CroFab and Anavip Administered to Treat US Rattlesnake Envenomation

Analysis shows patients treated with CroFab® require fewer total vials of antivenom, and fewer administrations to achieve control, than Anavip.
15 Mar 2023

New economic analysis of Voraxaze® (glucarpidase) in patients with delayed methotrexate elimination

Model simulation shows cost of timely Voraxaze® use is offset by shorter hospital stays and associated with substantially improved clinical outcomes